AR012970A1 - DRUG SUPPLY DEVICES FOR THE ADMINISTRATION OF A THERAPEUTIC AGENT - Google Patents
DRUG SUPPLY DEVICES FOR THE ADMINISTRATION OF A THERAPEUTIC AGENTInfo
- Publication number
- AR012970A1 AR012970A1 ARP980102783A ARP980102783A AR012970A1 AR 012970 A1 AR012970 A1 AR 012970A1 AR P980102783 A ARP980102783 A AR P980102783A AR P980102783 A ARP980102783 A AR P980102783A AR 012970 A1 AR012970 A1 AR 012970A1
- Authority
- AR
- Argentina
- Prior art keywords
- acetamide
- methyl
- alkyl groups
- group
- methylformamide
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 4
- 229940079593 drug Drugs 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 abstract 4
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- KDISMIMTGUMORD-UHFFFAOYSA-N 1-acetylpiperidine Chemical compound CC(=O)N1CCCCC1 KDISMIMTGUMORD-UHFFFAOYSA-N 0.000 abstract 2
- MXRPNYMMDLFYDL-YFKPBYRVSA-N AMCC Chemical compound CNC(=O)SC[C@@H](C(O)=O)NC(C)=O MXRPNYMMDLFYDL-YFKPBYRVSA-N 0.000 abstract 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 abstract 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 abstract 2
- KOCFTADHOAAXFC-UHFFFAOYSA-N HMMF Chemical compound OCN(C)C=O KOCFTADHOAAXFC-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- MNQOPPDTVHYCEZ-UHFFFAOYSA-N n-(hydroxymethyl)formamide Chemical compound OCNC=O MNQOPPDTVHYCEZ-UHFFFAOYSA-N 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- UMJPVWFIBILILQ-UHFFFAOYSA-N 3-methyl-2-propan-2-ylbutanamide Chemical compound CC(C)C(C(C)C)C(N)=O UMJPVWFIBILILQ-UHFFFAOYSA-N 0.000 abstract 1
- MGDMDXTUKUIEGV-UHFFFAOYSA-N C(C)(C)CC(=O)N.C(C)C(C(=O)N)CC Chemical compound C(C)(C)CC(=O)N.C(C)C(C(=O)N)CC MGDMDXTUKUIEGV-UHFFFAOYSA-N 0.000 abstract 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 abstract 1
- PVCJKHHOXFKFRP-UHFFFAOYSA-N N-acetylethanolamine Chemical compound CC(=O)NCCO PVCJKHHOXFKFRP-UHFFFAOYSA-N 0.000 abstract 1
- -1 N-acetylmorpholine acrylamide Chemical compound 0.000 abstract 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000004970 halomethyl group Chemical group 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- CSSWCWIUAZSBHV-UHFFFAOYSA-N n,n-bis(2-hydroxyethyl)acetamide Chemical compound OCCN(C(=O)C)CCO CSSWCWIUAZSBHV-UHFFFAOYSA-N 0.000 abstract 1
- JVAGOJYCQRMSBT-UHFFFAOYSA-N n-(dihydroxymethyl)formamide Chemical compound OC(O)NC=O JVAGOJYCQRMSBT-UHFFFAOYSA-N 0.000 abstract 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 abstract 1
- 229940080818 propionamide Drugs 0.000 abstract 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Uso de una sustancia o composicion para preparar un medicamento para usar en un método de tratamiento de una infeccion viral o microbiana o un síndromede desgaste, caraterizado porque la sustancia o composicion incluye al menos uno de N,N-dimetilformamida (DMF); N-hidroximetil-N-metilformamida (HMMF);N-hidroximetilformamida (HMF); dihidroximetilformamida (DHMF); N-acetil-S- (N-metilcarbamoil) cisteína (AMCC); N-metilformamida (NMF); dimetilsulfoxido(DMSO); formamida, acetamida; metilacetamida, dimetilacetamida, dietilacetamida isopropilacetamida; diisopropilacetamida; N-acetilpiperidina; N-(beta-hidroxietil)acetamida; N,N-di (beta-hidroxietil) acetamida; N-acetilmorfolina acrilamida; propionamida; N-flluorometil-N-metil-formamida; piridin-N-oxido, ouna amida de la formula general R3-CO-NR1R2, en la cual R1 y R2 son independientemente seleccionados del grupo que consiste en H, metilo,halometilo, grupos C2-3 alquilo saturados e insaturados, y grupos alquilo hidroxilados; o R1 y R2 se seleccionan juntos del grupo que consiste en (CH2)4,(CH2)5, y (CH2)2O(CH2)2; y R3 es seleccionado del grupo que consiste en H, metilo y grupos alquilo C2-C3 saturados e insaturados; y mezclas decualesquiera dos o más delos mismos y el método inlcuye administrar el medicamento a un animal que necesita el tratamiento.Use of a substance or composition to prepare a medicament for use in a method of treating a viral or microbial infection or attrition syndrome, characterized in that the substance or composition includes at least one of N, N-dimethylformamide (DMF); N-hydroxymethyl-N-methylformamide (HMMF), N-hydroxymethylformamide (HMF); dihydroxymethylformamide (DHMF); N-acetyl-S- (N-methylcarbamoyl) cysteine (AMCC); N-methylformamide (NMF); dimethyl sulfoxide (DMSO); formamide, acetamide; methylacetamide, dimethylacetamide, diethylacetamide isopropylacetamide; diisopropylacetamide; N-acetylpiperidine; N- (beta-hydroxyethyl) acetamide; N, N-di (beta-hydroxyethyl) acetamide; N-acetylmorpholine acrylamide; propionamide; N-flluoromethyl-N-methyl-formamide; pyridin-N-oxide, or an amide of the general formula R3-CO-NR1R2, in which R1 and R2 are independently selected from the group consisting of H, methyl, halomethyl, C2-3 saturated and unsaturated alkyl groups, and alkyl groups hydroxylated; or R1 and R2 are selected together from the group consisting of (CH2) 4, (CH2) 5, and (CH2) 2O (CH2) 2; and R3 is selected from the group consisting of H, methyl, and saturated and unsaturated C2-C3 alkyl groups; and mixtures of any two or more thereof and the method includes administering the drug to an animal in need of treatment.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/874,425 US5935597A (en) | 1995-12-15 | 1997-06-13 | Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR012970A1 true AR012970A1 (en) | 2000-11-22 |
Family
ID=25363728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980102783A AR012970A1 (en) | 1997-06-13 | 1998-06-11 | DRUG SUPPLY DEVICES FOR THE ADMINISTRATION OF A THERAPEUTIC AGENT |
Country Status (34)
| Country | Link |
|---|---|
| EP (1) | EP1011567A1 (en) |
| JP (1) | JP4531141B2 (en) |
| KR (1) | KR20010013709A (en) |
| CN (1) | CN1260703A (en) |
| AP (1) | AP1629A (en) |
| AR (1) | AR012970A1 (en) |
| AU (1) | AU7831598A (en) |
| BG (1) | BG103997A (en) |
| BR (1) | BR9810095A (en) |
| CA (1) | CA2295176A1 (en) |
| CZ (1) | CZ298510B6 (en) |
| EA (1) | EA200000011A1 (en) |
| EE (1) | EE9900562A (en) |
| ES (1) | ES2161187B1 (en) |
| FI (1) | FI19992648A (en) |
| GB (1) | GB2341319B (en) |
| HU (1) | HUP0003034A2 (en) |
| ID (1) | ID23516A (en) |
| IL (2) | IL133396A0 (en) |
| IS (1) | IS5289A (en) |
| LT (1) | LT4714B (en) |
| LV (1) | LV12490B (en) |
| NO (1) | NO996117L (en) |
| NZ (1) | NZ501669A (en) |
| OA (1) | OA11307A (en) |
| PL (1) | PL196256B1 (en) |
| RO (1) | RO121252B1 (en) |
| SI (1) | SI20191A (en) |
| SK (1) | SK172299A3 (en) |
| TN (1) | TNSN98086A1 (en) |
| TR (1) | TR200000540T2 (en) |
| WO (1) | WO1998056325A1 (en) |
| YU (1) | YU66099A (en) |
| ZA (1) | ZA984649B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP2006003648A0 (en) * | 2003-12-05 | 2006-06-30 | Namibia Medical Invest Pty Ltd | Patch |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE60941B1 (en) * | 1986-07-10 | 1994-09-07 | Elan Transdermal Ltd | Transdermal drug delivery device |
| US4855294A (en) * | 1988-09-06 | 1989-08-08 | Theratech, Inc. | Method for reducing skin irritation associated with drug/penetration enhancer compositions |
| US5534260A (en) * | 1989-02-23 | 1996-07-09 | University Of Utah | Percutaneous drug delivery system |
| US5028435A (en) * | 1989-05-22 | 1991-07-02 | Advanced Polymer Systems, Inc. | System and method for transdermal drug delivery |
| US5624912A (en) * | 1991-08-21 | 1997-04-29 | Burcoglu; Arsinur | Method of treating HIV infection and related secondary infections with defibrotide |
| EP0626945B1 (en) * | 1992-02-20 | 1998-04-22 | Merrell Pharmaceuticals Inc. | Sulfonic acid derivatives in the treatment of viral diseases |
| NZ501172A (en) * | 1995-12-15 | 2000-04-28 | Cyropreservation Technologies | Composition for organ cryopreservation comprising substituted amides |
-
1998
- 1998-05-29 ZA ZA9804649A patent/ZA984649B/en unknown
- 1998-06-09 BR BR9810095-5A patent/BR9810095A/en not_active Application Discontinuation
- 1998-06-09 SK SK1722-99A patent/SK172299A3/en unknown
- 1998-06-09 RO RO99-01313A patent/RO121252B1/en unknown
- 1998-06-09 EP EP98926488A patent/EP1011567A1/en not_active Withdrawn
- 1998-06-09 SI SI9820040A patent/SI20191A/en unknown
- 1998-06-09 EA EA200000011A patent/EA200000011A1/en unknown
- 1998-06-09 CZ CZ0447399A patent/CZ298510B6/en not_active IP Right Cessation
- 1998-06-09 CA CA002295176A patent/CA2295176A1/en not_active Abandoned
- 1998-06-09 IL IL13339698A patent/IL133396A0/en active IP Right Grant
- 1998-06-09 ES ES009950072A patent/ES2161187B1/en not_active Expired - Lifetime
- 1998-06-09 NZ NZ501669A patent/NZ501669A/en unknown
- 1998-06-09 GB GB9929189A patent/GB2341319B/en not_active Expired - Fee Related
- 1998-06-09 AU AU78315/98A patent/AU7831598A/en not_active Abandoned
- 1998-06-09 PL PL338439A patent/PL196256B1/en unknown
- 1998-06-09 HU HU0003034A patent/HUP0003034A2/en unknown
- 1998-06-09 YU YU66099A patent/YU66099A/en unknown
- 1998-06-09 AP APAP/P/1999/001708A patent/AP1629A/en active
- 1998-06-09 JP JP50311899A patent/JP4531141B2/en not_active Expired - Fee Related
- 1998-06-09 KR KR1019997011724A patent/KR20010013709A/en not_active Application Discontinuation
- 1998-06-09 TR TR2000/00540T patent/TR200000540T2/en unknown
- 1998-06-09 ID IDW20000042A patent/ID23516A/en unknown
- 1998-06-09 EE EEP199900562A patent/EE9900562A/en unknown
- 1998-06-09 CN CN98806085A patent/CN1260703A/en active Pending
- 1998-06-09 WO PCT/US1998/011956 patent/WO1998056325A1/en active IP Right Grant
- 1998-06-11 AR ARP980102783A patent/AR012970A1/en not_active Application Discontinuation
- 1998-06-12 TN TNTNSN98086A patent/TNSN98086A1/en unknown
-
1999
- 1999-12-08 IS IS5289A patent/IS5289A/en unknown
- 1999-12-09 FI FI992648A patent/FI19992648A/en unknown
- 1999-12-09 IL IL133396A patent/IL133396A/en not_active IP Right Cessation
- 1999-12-10 OA OA9900279A patent/OA11307A/en unknown
- 1999-12-10 NO NO996117A patent/NO996117L/en not_active Application Discontinuation
- 1999-12-13 BG BG103997A patent/BG103997A/en unknown
- 1999-12-20 LT LT99-148A patent/LT4714B/en not_active IP Right Cessation
-
2000
- 2000-02-02 LV LVP-99-182A patent/LV12490B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2042520T3 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING LEVODOPA METHYL ESTER, PREPARATION AND THERAPEUTIC APPLICATIONS THEREOF. | |
| BR0012804A (en) | Amine and amide derivatives as ligands for the neuropeptide receptor y5 useful in the treatment of obesity and other disorders | |
| KR950002785A (en) | Parathyroid hormone and raloxyphene to increase bone mass | |
| DE69529670T2 (en) | OXAZOLIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| NO992336L (en) | Raf kinase inhibitors | |
| ATE316786T1 (en) | TREATMENT OF MUCOSITIS | |
| ES2116801T3 (en) | USE OF ADAMANTANE DERIVATIVES FOR THE TREATMENT OF TINNITUS. | |
| BR0209468A (en) | Pharmaceutically acceptable compound or salts or solvates thereof, pharmaceutical composition, use of a compound, and method of treating an HPP-mediated disease or condition | |
| AR205189A1 (en) | DERIVATIVES OF N- (1 "-METOXI-CARBONILETIL) -N- (FURAN- (2") CARBONIL) 2-6-DIMETILANILINA USEFUL AS MICROBICIDE AGENTS LESS FOR PHARMACEUTICAL USES AND PROCEDURE FOR OBTAINING THEM | |
| AR031152A1 (en) | NEW TREATMENTS FOR THE CONCERNED LEG SYNDROME | |
| PT892794E (en) | N-HYDROXYMETHYL-THALIDOMIDE PRODUTS ACIDS OF IMMUNOMODULATORY EFFECT | |
| HRP20100577T1 (en) | Use of agomelatine to obtain a medication aimed at treating generalised anxiety disorder | |
| RU93032613A (en) | PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF PATIENTS WITH PROLONGED COAGULATION TIME, METHOD OF TREATING PATIENTS, USING THE EPI INHIBITOR FOR OBTAINING THE PHARMACEUTICAL PREPARATION | |
| RU95112620A (en) | Veterinary implantable preparation for animal biological rhythm regulation | |
| ES2196049T3 (en) | USE OF 2- (2-ALQUILFENILAMINO) OXAZOLINAS AND -TIAZOLINAS FOR THE MANUFACTURE OF A MEDICINAL WITH ALFA 2 ADRENERGIC EFFECT. | |
| KR910018381A (en) | Improved Ergoline-8-Carboxamide | |
| HUP0200152A2 (en) | Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites | |
| AR012970A1 (en) | DRUG SUPPLY DEVICES FOR THE ADMINISTRATION OF A THERAPEUTIC AGENT | |
| FR2595695B1 (en) | DERIVATIVES OF N - (((HYDROXY-2 PHENYL) (PHENYL) METHYLENE) AMINO-2) ETHYL) ACETAMIDE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | |
| KR950013509A (en) | Melatonin derivatives useful for the treatment of asynchronous disorders | |
| ES2181702T3 (en) | MELATONIN DERIVATIVES FOR USE IN THE TREATMENT OF ILLNESS IS SLEEP. | |
| RU2011131532A (en) | METHOD FOR TREATING INSOMNIA | |
| DK0607777T3 (en) | Use of leflunomide to inhibit interleukin 8 | |
| NZ332030A (en) | Sulfonamide substituted chromans, processes for their preparation, their use as a medicament and pharmaceutical preparations comprising them | |
| NO169229C (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 5- (3-ALKYL-5-TERT.BUTYL-4-HYDROXYPHENYL) -2-AMINO-6H-1,3,4-THIADIAZINES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |